Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christina Twyman-Saint Victor"'
Autor:
Robert H. Vonderheide, Christina Twyman-Saint Victor, Andy J. Minn, Jorge Henao-Mejia, Jonathan J. Kotzin, Hannah Dada, Andrew J. Rech
Immunotherapy in pancreatic ductal adenocarcinoma (PDA) remains a difficult clinical problem despite success in other disease types with immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell therapy. Mechanisms driving immunosuppressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb3596efca2f3dc0cb396dd7f12ef8d
https://doi.org/10.1158/0008-5472.c.6510188
https://doi.org/10.1158/0008-5472.c.6510188
Autor:
Robert H. Vonderheide, Christina Twyman-Saint Victor, Andy J. Minn, Jorge Henao-Mejia, Jonathan J. Kotzin, Hannah Dada, Andrew J. Rech
Supplemental Methods: Mouse strains and flow cytometry antibodies Supplemental Figure 1: Individual tumor kinetics of the unirradiated tumor in the PDA model. Tumor kinetics (mean and individual) of the irradiated tumor and survival in the B16-F10 me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3981ee8baea49c564aef73279598404e
https://doi.org/10.1158/0008-5472.22418657.v1
https://doi.org/10.1158/0008-5472.22418657.v1
Autor:
Jianxin Wang, May Tun Saung, Keyu Li, Juan Fu, Kenji Fujiwara, Nan Niu, Stephen Muth, Junke Wang, Yao Xu, Noah Rozich, Haley Zlomke, Sophia Chen, Birginia Espinoza, MacKenzie Henderson, Vanessa Funes, Brian Herbst, Ding Ding, Christina Twyman-Saint Victor, Qihong Zhao, Amol Narang, Jin He, Lei Zheng
Publikováno v:
Journal of Experimental Medicine. 219
The resistance of pancreatic ductal adenocarcinoma (PDAC) to immune checkpoint inhibitors (ICIs) is attributed to the immune-quiescent and -suppressive tumor microenvironment (TME). We recently found that CCR2 and CCR5 were induced in PDAC following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8b4d12f083293e2998af27723d3228c
https://doi.org/10.1084/jem.20211631
https://doi.org/10.1084/jem.20211631
Autor:
Jorge Henao-Mejia, Christina Twyman-Saint Victor, Jonathan J. Kotzin, Hannah Dada, Robert H. Vonderheide, Andrew J. Rech, Andy J. Minn
Immunotherapy in pancreatic ductal adenocarcinoma (PDA) remains a difficult clinical problem despite success in other disease types with immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell therapy. Mechanisms driving immunosuppressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe26e7f1b0f808667401b6e91141f731
https://europepmc.org/articles/PMC6415684/
https://europepmc.org/articles/PMC6415684/
Autor:
Hannah Dada, Kristen E. Pauken, Rosemarie Mick, Amit Maity, Bihui Xu, Xiaowei Xu, Hemant Ishwaran, Tara C. Gangadhar, Christina Twyman-Saint Victor, Ramin S. Herati, Joseph L. Benci, Dana Patsch, Kathleen D. Mansfield, Andy J. Minn, Pamela M. Odorizzi, Andrew J. Rech, Ravi K. Amaravadi, Stephen M. Hahn, Ramesh Rengan, Lynn M. Schuchter, Michael Feldman, E. John Wherry, Daniel A. Pryma, Erietta Stelekati, Robert H. Vonderheide
Publikováno v:
Nature
Immune checkpoint inhibitors result in impressive clinical responses, but optimal results will require combination with each other and other therapies. This raises fundamental questions about mechanisms of non-redundancy and resistance. Here we repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13c45c53c6465fe31fb108982da1b12
https://doi.org/10.1038/nature14292
https://doi.org/10.1038/nature14292
Publikováno v:
Cancer Research. 79:4988-4988
Background: Melanoma is currently the fifth most common cancer in men and sixth most common in women with an estimate of 9,320 deaths from the disease in the United States. Anti-PD1, an immune checkpoint inhibitor, is FDA approved to treat metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49c8d45745155141349d02b59b449c03
https://doi.org/10.1158/1538-7445.am2019-4988
https://doi.org/10.1158/1538-7445.am2019-4988
Autor:
Lisa Cucolo, David Lee, Tony J. Wu, Robert H. Vonderheide, Hannah Dada, Bihui Xu, Lynn M. Schuchter, Tara C. Gangadhar, Christina Twyman-Saint Victor, Michael Feldman, E. John Wherry, Yu Qiu, Kristen E. Pauken, Andy J. Minn, Joseph L. Benci, Hemant Ishwaran, Amit Maity, Alexander C. Huang, Ravi K. Amaravadi
Therapeutic blocking of the PD1 pathway results in significant tumor responses but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35faecb7702cd22a48b3a3677f37d6f4
https://europepmc.org/articles/PMC5385895/
https://europepmc.org/articles/PMC5385895/
Autor:
Andy J. Minn, Christina Twyman-Saint Victor, Hannah Dada, Robert H. Vonderheide, Andrew J. Rech
Publikováno v:
Cancer Research. 78:2985-2985
Despite the success of cancer immunotherapy in many disease types, pancreatic ductal adenocarcinoma (PDA) is notably unresponsive to immune checkpoint blockade (ICB) with αPD1 and/or αCTLA4. The mechanism of resistance is poorly understood, but tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e0c7d9191417367ddd05421e6444414
https://doi.org/10.1158/1538-7445.am2018-2985
https://doi.org/10.1158/1538-7445.am2018-2985
Autor:
Barzin Y. Nabet, Taewon Yoon, Diana J. Azzam, Jos Jonkers, Joyce M. Slingerland, Brianne Z. Wiemann, Andy J. Minn, Christina Twyman-Saint Victor, Hemant Ishwaran, Yu Qiu, Petra ter Brugge, Tony J. Wu, Mirjam C. Boelens, Bihui Xu
SummaryStromal communication with cancer cells can influence treatment response. We show that stromal and breast cancer (BrCa) cells utilize paracrine and juxtacrine signaling to drive chemotherapy and radiation resistance. Upon heterotypic interacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d2293c70e3c5877d068ee8ed900f6f
Autor:
Joseph L. Benci, Erietta Stelekati, Tara C. Gangadhar, Daniel A. Pryma, Christina Twyman-Saint Victor, Pamela M. Odorizzi, Ramesh Rengan, Lynn M. Schuchter, Ravi K. Amaravadi, Michael Feldman, Rosemarie Mick, Hemant Ishwaran, Hannah Dada, Andrew J. Rech, Xiaowei Xu, Bihui Xu, Andy J. Minn, Ramin S. Herati, Steve Hahn, Kristen E. Pauken, Robert H. Vonderheide, John Wherry, Amit Maity
Publikováno v:
Cancer Research. 76:PR05-PR05
Immune checkpoint inhibitors result in impressive clinical responses but optimal results will require combination with each other and other therapies. This raises fundamental questions about mechanisms of non-redundancy and resistance. Here, we repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab2a7adf71ab1e5f8e8ff82f05ca4821
https://doi.org/10.1158/1538-7445.fbcr15-pr05
https://doi.org/10.1158/1538-7445.fbcr15-pr05